相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients
Xin Zhou et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1
Daniel J. Rubins et al.
MOLECULAR IMAGING AND BIOLOGY (2021)
Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
Pushpamali De Silva et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Maohua Li et al.
SCIENTIFIC REPORTS (2021)
Barriers to antibody therapy in solid tumors, and their solutions
Yasuhiro Matsumura
CANCER SCIENCE (2021)
Directing evolution of novel ligands by mRNA display
Golnaz Kamalinia et al.
CHEMICAL SOCIETY REVIEWS (2021)
Directed evolution of cyclic peptides for inhibition of autophagy
Joshua P. Gray et al.
CHEMICAL SCIENCE (2021)
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Gaochao Lv et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Engineered Protein Scaffolds as Next-Generation Therapeutics
Michaela Gebauer et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Purification of poly-dA oligonucleotides and mRNA-protein fusions with dT25-OAS resin
Brian J. Engel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Screening and production of an affibody inhibiting the interaction of the PD1/PD-L1 immune checkpoint
Lei Jing et al.
PROTEIN EXPRESSION AND PURIFICATION (2020)
mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1)
Golnaz Kamalinia et al.
ACS CHEMICAL BIOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model
Jun Zhao et al.
ACS OMEGA (2020)
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins
Emelie Foord et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
Jacob J. Orme et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Mammalian Expression and In Situ Biotinylation of Extracellular Protein Targets for Directed Evolution
Brian J. Grindel et al.
ACS OMEGA (2020)
Site-Specific Immuno-PET Tracer to Image PD-L1
Haley L. Wissler et al.
MOLECULAR PHARMACEUTICS (2019)
The EMBL-EBI search and sequence analysis tools APIs in 2019
Fabio Madeira et al.
NUCLEIC ACIDS RESEARCH (2019)
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Dhiraj Kumar et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
Wojciech G. Lesniak et al.
MOLECULAR IMAGING (2019)
Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation (vol 55, pg 4162, 2019)
Kuan Hu et al.
CHEMICAL COMMUNICATIONS (2019)
Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
Elaine M. Jagoda et al.
MOLECULAR IMAGING (2019)
Synthesis and Biologic Evaluation of a Novel F-18-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Review of cancer treatment with immune checkpoint inhibitors
Christiane Thallinger et al.
WIENER KLINISCHE WOCHENSCHRIFT (2018)
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
Feifei Teng et al.
CANCER LETTERS (2018)
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody
Dan Li et al.
MOLECULAR PHARMACEUTICS (2018)
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
Katrijn Broos et al.
THERANOSTICS (2018)
Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer
Ravindra A. De Silva et al.
MOLECULAR PHARMACEUTICS (2018)
Cis/trans isomerization of proline peptide bonds in the backbone of cyclic disulfide-bridged peptides
Qiang Sui et al.
PEPTIDE SCIENCE (2018)
In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
Dinko E. Gonzalez Trotter et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies
Lan Wang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
Anti-PD-L1 peptide improves survival in sepsis
Yuichiro Shindo et al.
JOURNAL OF SURGICAL RESEARCH (2017)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
Samit Chatterjee et al.
MOLECULAR IMAGING (2017)
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Fei Zhang et al.
CELL DISCOVERY (2017)
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
Charles Caldwell et al.
SCIENTIFIC REPORTS (2017)
Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Katarzyna Magiera-Mularz et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2017)
In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma
Do Won Hwang et al.
CANCER LETTERS (2017)
Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications
Stephen V. Fiacco et al.
CHEMBIOCHEM (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sorensen et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Serum Stable Natural Peptides Designed by mRNA Display
Shannon M. Howell et al.
SCIENTIFIC REPORTS (2014)
Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells
Amelie Croset et al.
JOURNAL OF BIOTECHNOLOGY (2012)
In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors
Yollete V. Guillen Schlippe et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels
Vladimir Tolmachev et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Diversity of Phage-Displayed Libraries of Peptides during Panning and Amplification
Ratmir Derda et al.
MOLECULES (2011)
Target-specific delivery of peptide-based probes for PET imaging
Kai Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
J. Lofblom et al.
FEBS LETTERS (2010)
Design of an Optimized Scaffold for Affibody Molecules
Joachim Feldwisch et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Kinetics and Equilibria of Cis/Trans Isomerization of Secondary Amide Peptide Bonds in Linear and Cyclic Peptides
Khanh Nguyen et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2010)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Design of cyclic peptides that bind protein surfaces with antibody-like affinity
Steven W. Millward et al.
ACS CHEMICAL BIOLOGY (2007)
Structural basis for molecular recognition in an Affibody:: Affibody complex
Christofer Lendel et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Tumor Imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova et al.
CANCER RESEARCH (2006)
Selection and characterization of HER2/neu-binding affibody ligands
M Wikman et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2004)
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications
H Maeda et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
分享论文
